Literature DB >> 15280463

Identification of protein tyrosine kinases required for B-cell- receptor-mediated activation of an Epstein-Barr Virus immediate-early gene promoter.

Sandra Lavens1, Emmanuel A Faust, Fang Lu, Michele Jacob, Messele Leta, Paul M Lieberman, Ellen Puré.   

Abstract

Epstein-Barr Virus (EBV) is a potentially oncogenic herpesvirus that infects >90% of the world's population. EBV exists predominantly as a latent infection in B lymphocytes, with periodic lytic-cycle reactivation essential for cellular and host transmission. Viral reactivation can be stimulated by ligand-induced activation of B-cell-receptor (BCR)-coupled signaling pathways. The critical first step in the transition from latency to the lytic cycle is the expression of the viral immediate-early gene BZLF1 through the transcription activation of its promoter, Zp. However, the BCR-coupled signal transduction cascade(s) leading to the induction of Zp and the expression of the BZLF1 gene product, Zta, is currently unclear. A major obstacle to delineating the relevant signal transduction events has been the lack of a model of EBV infection that is amenable to genetic manipulation. The use of the avian B-cell line DT40 has proven to be a powerful tool for delineating BCR-mediated signal transduction pathways that appear to be highly conserved between avian and mammalian systems. We demonstrate that the DT40 cell line is a robust and genetically tractable system for the study of BCR-mediated signaling pathways leading to transcriptional activation of BZLF1. Using this system, we demonstrate that activation of Zp requires the BCR-coupled protein tyrosine kinases Syk and Btk and that it is positively regulated by Lyn. Thus, the use of DT40 cells has allowed us to delineate the early signaling components required for BCR-dependent reactivation of latent EBV, and this system is likely to prove useful for further dissection of the downstream signaling cascades involved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280463      PMCID: PMC479085          DOI: 10.1128/JVI.78.16.8543-8551.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  The Epstein-Barr virus-induced Ca2+/calmodulin-dependent kinase type IV/Gr promotes a Ca(2+)-dependent switch from latency to viral replication.

Authors:  T Chatila; N Ho; P Liu; S Liu; G Mosialos; E Kieff; S H Speck
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

2.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

3.  Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.

Authors:  K Takada; Y Ono
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

4.  Disruption of Epstein-Barr virus latency in the absence of phosphorylation of ZEBRA by protein kinase C.

Authors:  Ayman S El-Guindy; Lee Heston; Yoshimi Endo; Myung-Sam Cho; George Miller
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Stimulation of CREB binding protein nucleosomal histone acetyltransferase activity by a class of transcriptional activators.

Authors:  C J Chen; Z Deng; A Y Kim; G A Blobel; P M Lieberman
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

6.  Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1.

Authors:  E Flemington; S H Speck
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

7.  Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1.

Authors:  E Flemington; S H Speck
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  Identification of Epstein-Barr virus genes expressed during the early phase of virus replication and during lymphocyte immortalization.

Authors:  J Sample; A Tanaka; G Lancz; M Nonoyama
Journal:  Virology       Date:  1984-11       Impact factor: 3.616

9.  Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.

Authors:  A Chevallier-Greco; E Manet; P Chavrier; C Mosnier; J Daillie; A Sergeant
Journal:  EMBO J       Date:  1986-12-01       Impact factor: 11.598

10.  Epstein-Barr virus bicistronic mRNAs generated by facultative splicing code for two transcriptional trans-activators.

Authors:  E Manet; H Gruffat; M C Trescol-Biemont; N Moreno; P Chambard; J F Giot; A Sergeant
Journal:  EMBO J       Date:  1989-06       Impact factor: 11.598

View more
  5 in total

1.  Contribution of C/EBP proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells.

Authors:  Jian Huang; Gangling Liao; Honglin Chen; Frederick Y Wu; Lindsey Hutt-Fletcher; Gary S Hayward; S Diane Hayward
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 2.  Emerging Proviral Roles of Caspases during Lytic Replication of Gammaherpesviruses.

Authors:  Tate Tabtieng; Marta M Gaglia
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

3.  Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation.

Authors:  Pei-Fang Tsai; Sue-Jane Lin; Pei-Lun Weng; Shu-Chun Tsai; Jiun-Han Lin; Ya-Ching Chou; Ching-Hwa Tsai
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

Review 4.  Effects of BTK signalling in pathogenic microorganism infections.

Authors:  Bingjue Ye; Cheng Zhou; Huiting Guo; Min Zheng
Journal:  J Cell Mol Med       Date:  2019-08-08       Impact factor: 5.310

5.  B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.

Authors:  James C Romero-Masters; Shane M Huebner; Makoto Ohashi; Jillian A Bristol; Bayleigh E Benner; Elizabeth A Barlow; Gail L Turk; Scott E Nelson; Dana C Baiu; Nicholas Van Sciver; Erik A Ranheim; Jenny Gumperz; Nathan M Sherer; Paul J Farrell; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2020-02-14       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.